Fisetin has been shown to be an effective drug for treating inflammation-related lung illnesses such as COPD 57, reducing NF-κB binding in the IL-8 promoter region in NCI-H292 lung epithelial cells, resulting in reduced IL-8 production in response to TNF-α 57. Here, NFKB1 is linked to chronic obstructive pulmonary disease.